ConductScience.org, home

Paper42014656

The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications.

Mirzaee F and 3 others. Ann Hematol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications. Papers, record 42014656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42014656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The role of hydroxyurea in modulating miRNA expression in sickle cell disease: molecular mechanisms and therapeutic implications.
PubMed
Journal
Ann Hematol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-21
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mirzaee FFaezeh
2Khamoushi AAtefeh
3Dolati RRoghayeh
4Abbasi AAmirhosein

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anemia, Sickle CellMajor topic
HydroxyureaMajor topic
MicroRNAsMajor topic
Gene Expression RegulationMajor topic
Antisickling AgentsMajor topic
Humans
Animals

Source PubMed

Download CSV of topics

References80

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138188295The microRNA target site profile is a novel biomarker in the immunotherapy response.Front Oncol2023https://conductscience.org/library/papers/38188295PubMed
240087738Balancing benefits and burdens: a systematic review on ethical and social dimensions of gene and cell therapies for hereditary blood diseases.BMC Med Ethics2025https://conductscience.org/library/papers/40087738PubMed
340589088Transferrin Purification, Biophysical Characterization, and Lung Biodistribution in Sickle Cell Disease Mice.Biotechnol Bioeng2025https://conductscience.org/library/papers/40589088PubMed
433807258Distinct miRNA Signatures and Networks Discern Fetal from Adult Erythroid Differentiation and Primary from Immortalized Erythroid Cells.Int J Mol Sci2021https://conductscience.org/library/papers/33807258PubMed
528696844Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea.Hemoglobin2017https://conductscience.org/library/papers/28696844PubMed
636677692Recent Advances on Small-Molecule Antagonists Targeting TLR7.Molecules2023https://conductscience.org/library/papers/36677692PubMed
739512697Decoding the Promise and Challenges of miRNA-Based Cancer Therapies: An Essential Update on miR-21, miR-34, and miR-155.Int J Med Sci2024https://conductscience.org/library/papers/39512697PubMed
835080707Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size.Pharm Res2022https://conductscience.org/library/papers/35080707PubMed
936815490The future of sickle cell disease therapeutics rests in genomics.Dis Model Mech2023https://conductscience.org/library/papers/36815490PubMed
1040187617MicroRNAs in sickle cell disease: A comprehensive review.Gene2025https://conductscience.org/library/papers/40187617PubMed
1121921042Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia.Blood2011https://conductscience.org/library/papers/21921042PubMed
1234247076Global research on the air quality status in response to the electrification of vehicles.Sci Total Environ2021https://conductscience.org/library/papers/34247076PubMed
1334521246miR-210 hypoxamiR in Angiogenesis and Diabetes.Antioxid Redox Signal2022https://conductscience.org/library/papers/34521246PubMed
1438802815Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.BMC Health Serv Res2024https://conductscience.org/library/papers/38802815PubMed
1535126450Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey.Front Genet2021https://conductscience.org/library/papers/35126450PubMed
1624839362Hydroxyurea in sickle cell disease: drug review.Indian J Hematol Blood Transfus2014https://conductscience.org/library/papers/24839362PubMed
1735750558Determinants of severity in sickle cell disease.Blood Rev2022https://conductscience.org/library/papers/35750558PubMed
1840796944In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery.Nat Biomed Eng2026https://conductscience.org/library/papers/40796944PubMed
1917482553An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling.Cell2007https://conductscience.org/library/papers/17482553PubMed
2036295630miRNA Expression Associated with HbF in Saudi Sickle Cell Anemia.Medicina (Kaunas)2022https://conductscience.org/library/papers/36295630PubMed

See all 80 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42014656

GET https://conductscience.org/api/papers/v1/42014656/references?page=2